News
Here's Why Editas Medicine Rose as Much as 15.9% Monday
Shares of gene editing leader Editas Medicine (NASDAQ: EDIT) rose nearly 16% Monday on heavy trading volume, most of which occurred shortly after the market opened. The number of shares traded in the
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
When GW Pharmaceuticals (NASDAQ: GWPH) announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. There were at least
BOIRON : Déclaration mensuelle des droits de vote au 31 juillet 2017
Le 8 août 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
3 Stocks Hitting 52-Week Lows: Time to Go Bargain Shopping?
There's an old saying that a rising tide lifts all boats. That's true -- but only if the boats don't have holes in them. With the S&P 500 index hitting an all-time high recently, most stocks are
Why Teva Pharmaceutical Industries, Intrepid Potash, and Ensco Slumped Today
Monday was another good day for stocks, as major benchmarks continued their slow but steady ascent. Without much in the way of market-moving news on the geopolitical or macroeconomic fronts, investors
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
Emergent Biosolutions Inc Diversifies Its Revenue
One knock on Emergent Biosolutions (NYSE: EBS) has always been its dependence on anthrax vaccine BioThrax, but management made good on its promise to diversify, moving toward its goal of having $1
bluebird bio Pauses During 2017 Data Blitz
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and
The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)
Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.Valeant Pharmaceuticals
Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market
Why Flexion Therapeutics Shares Shot 12.8% Higher in July
After the company hosted an investor's day on July 10, shares in Flexion Therapeutics (NASDAQ: FLXN) jumped 12.8% last month, according to S&P Global Market Intelligence.Flexion Therapeutics doesn't
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Here's Why Impax Laboratories Inc Jumped 18% In July
In response to receiving a double dose of good news from the Food and Drug Administration (FDA) and some bullish commentary from Wall Street, shares of Impax Laboratories (NASDAQ: IPXL), a maker of
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
These 3 Biotechs Just Crushed Analyst Expectations
Earnings season is under way, and biotech business appears to be booming. But it takes more than just a good quarter to know if a biotech is poised for sustainable, long-term growth. With many
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad Year
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One's Bill Mann consider how much worse Teva Pharmaceutical Industries (NYSE: TEVA) looks presently, after a second quarter
3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
3 Things You Need to Know About Marijuana Stock Cara Therapeutics
Cara Therapeutics (NASDAQ: CARA) announced its second-quarter financial results after the market closed on Thursday. The next day, Cara stock soared. But it wasn't because of the financial numbers
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
Why GW Pharmaceuticals Could Be a Gold Mine for Growth Investors
You've probably heard of the great California gold rush of the mid-19th century. Today, many are flocking to what has been called the "green rush" -- a major wave of money flowing into the marijuana
Tesla Speeds Ahead, While Teva Hits the Skids
On this Market Foolery podcast, host Chris Hill and Motley Fool One's Bill Mann discuss two very different companies with two wildly different places in the market today.As electric-car innovator